Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 8.46
APRI's Cash to Debt is ranked higher than
74% of the 771 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. APRI: 8.46 )
APRI' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 8.46

Interest Coverage No Debt
APRI's Interest Coverage is ranked higher than
85% of the 431 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 124.75 vs. APRI: No Debt )
APRI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: -13.66
M-Score: -5.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -691.64
APRI's Operating margin (%) is ranked lower than
56% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.93 vs. APRI: -691.64 )
APRI' s 10-Year Operating margin (%) Range
Min: -25298.53   Max: -86.86
Current: -691.64

-25298.53
-86.86
Net-margin (%) -674.55
APRI's Net-margin (%) is ranked lower than
56% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.07 vs. APRI: -674.55 )
APRI' s 10-Year Net-margin (%) Range
Min: -23786.76   Max: -83.71
Current: -674.55

-23786.76
-83.71
ROE (%) -154.37
APRI's ROE (%) is ranked lower than
56% of the 724 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. APRI: -154.37 )
APRI' s 10-Year ROE (%) Range
Min: -2412.81   Max: -22.79
Current: -154.37

-2412.81
-22.79
ROA (%) -72.66
APRI's ROA (%) is ranked lower than
55% of the 746 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.87 vs. APRI: -72.66 )
APRI' s 10-Year ROA (%) Range
Min: -195.49   Max: -22.08
Current: -72.66

-195.49
-22.08
ROC (Joel Greenblatt) (%) -1818.53
APRI's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.90 vs. APRI: -1818.53 )
APRI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4161.4   Max: -68.01
Current: -1818.53

-4161.4
-68.01
Revenue Growth (%) -45.00
APRI's Revenue Growth (%) is ranked lower than
54% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. APRI: -45.00 )
APRI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 105.1
Current: -45

0
105.1
EBITDA Growth (%) -33.00
APRI's EBITDA Growth (%) is ranked lower than
51% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. APRI: -33.00 )
APRI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 49.9
Current: -33

0
49.9
EPS Growth (%) -43.00
APRI's EPS Growth (%) is ranked higher than
51% of the 593 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. APRI: -43.00 )
APRI' s 10-Year EPS Growth (%) Range
Min: -44.3   Max: 78.2
Current: -43

-44.3
78.2
» APRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with APRI



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 8.50
APRI's P/B is ranked higher than
53% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. APRI: 8.50 )
APRI' s 10-Year P/B Range
Min: 1.43   Max: 127.5
Current: 8.5

1.43
127.5
P/S 44.84
APRI's P/S is ranked lower than
56% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. APRI: 44.84 )
APRI' s 10-Year P/S Range
Min: 0   Max: 2700
Current: 44.84

0
2700
EV-to-EBIT -3.53
APRI's EV-to-EBIT is ranked higher than
53% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 32.97 vs. APRI: -3.53 )
APRI' s 10-Year EV-to-EBIT Range
Min: 11.5   Max: 55.9
Current: -3.53

11.5
55.9
Current Ratio 1.61
APRI's Current Ratio is ranked higher than
59% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. APRI: 1.61 )
APRI' s 10-Year Current Ratio Range
Min: 0.12   Max: 85.68
Current: 1.61

0.12
85.68
Quick Ratio 1.59
APRI's Quick Ratio is ranked higher than
68% of the 759 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.67 vs. APRI: 1.59 )
APRI' s 10-Year Quick Ratio Range
Min: 0.12   Max: 85.68
Current: 1.59

0.12
85.68

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.50
APRI's Price/Net Cash is ranked higher than
91% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. APRI: 11.50 )
APRI' s 10-Year Price/Net Cash Range
Min: 3.4   Max: 281.25
Current: 11.5

3.4
281.25
Price/Net Current Asset Value 11.50
APRI's Price/Net Current Asset Value is ranked higher than
87% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. APRI: 11.50 )
APRI' s 10-Year Price/Net Current Asset Value Range
Min: 3.4   Max: 281.25
Current: 11.5

3.4
281.25
Price/Tangible Book 8.50
APRI's Price/Tangible Book is ranked higher than
60% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.53 vs. APRI: 8.50 )
APRI' s 10-Year Price/Tangible Book Range
Min: 2.1   Max: 90.15
Current: 8.5

2.1
90.15
Price/Median PS Value 1.30
APRI's Price/Median PS Value is ranked lower than
55% of the 806 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.23 vs. APRI: 1.30 )
APRI' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 125
Current: 1.3

0.08
125
Earnings Yield (Greenblatt) 1226.90
APRI's Earnings Yield (Greenblatt) is ranked higher than
99% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.00 vs. APRI: 1226.90 )
APRI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.8   Max: 1382.6
Current: 1226.9

1.8
1382.6
Forward Rate of Return (Yacktman) -16.95
APRI's Forward Rate of Return (Yacktman) is ranked higher than
53% of the 622 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. APRI: -16.95 )
APRI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -442   Max: -96.8
Current: -16.95

-442
-96.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:NXEN.Germany
Apricus Biosciences, Inc., was incorporated in Nevada in 1987. The Company is a pharmaceutical company, develops and commercializes pharmaceutical products that treat large patient populations with operations based in the United States. Its products have been developed utilizing its NexACTproprietary permeation enhancement technology. Its initial approved product is Vitaros approved in Canada for the treatment of erectile dysfunction ('ED') and its next in-line late stage product candidate is Femprox, for the treatment of female sexual arousal disorder ('FSAD'). It has also filed for approval of Vitaros for the treatment of ED in Europe through the Decentralized Approval Process ('DCP') and in Switzerland. Femprox has completed one Phase III clinical trial in China and the Company is developing a regulatory submission plan for additional clinical trials in the U.S., Canada and Europe. During the 2012 fiscal year, the Company operated in three active business segments: developing and commercializing pharmaceutical products, including those with its NexACT platform; sales of diagnostic products; and contract sales. On December 14, 2009, the Company acquired Bio-Quant, Inc. ('Bio-Quant'), a specialty biotech contract research organization ('CRO') based in San Diego, California. It currently own an approximate total of 72 registered trademarks as well as 38 pending trademark applications and 11 allowed pending trademark applications worldwide. It owns registered trademarks for Vitaros, Femprox and NexACT in certain countries and territories throughout the world.
» More Articles for APRI

Headlines

Articles On GuruFocus.com
CEO and CFO Buys Weekly Update May 29 2013 

More From Other Websites
Apricus Biosciences: Stay The Course With This Sexual Health Company Jul 23 2014
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jul 15 2014
Apricus Biosciences Announces the Launch of Its Topical Treatment for Erectile Dysfunction... Jun 16 2014
Apricus Biosciences upgraded to Buy from Hold at Cantor May 27 2014
APRICUS BIOSCIENCES, INC. Financials May 20 2014
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission... May 15 2014
Apricus' Q1 Loss Narrows May 13 2014
Apricus Biosciences (APRI) CEO Rich Pascoe on Q1 2014 Results - Earnings Call Transcript May 12 2014
Apricus Biosciences receives FDA clearance to begin clinical trial of RayVa May 12 2014
Apricus Biosciences reports Q1 EPS (9c), consensus (3c) May 12 2014
Apricus Biosciences Receives FDA Clearance to Begin Clinical Trial of RayVa(TM) for Secondary... May 12 2014
Apricus Biosciences Provides Corporate Update and First Quarter 2014 Financial Results May 12 2014
APRICUS BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report May 12 2014
Q1 2014 Apricus Biosciences Inc Earnings Release - After Market Close May 12 2014
Apricus Biosciences Announces Corporate Update and First Quarter 2014 Financial Results Conference... Apr 28 2014
Apricus Biosciences Announces National Phase Approval for Vitaros(R) in Spain Apr 24 2014
Apricus Biosciences Announces National Phase Approval for Vitaros(R) in Spain Apr 24 2014
Apricus Has Begun The Successful Launch Of Vitaros Apr 17 2014
Strength Seen in Apricus Biosciences (APRI): Stock Soars 18.9% Apr 17 2014
Apricus Biosciences granted national phase approval for Vitaros in Luxembourg Apr 03 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide